CIS BIOPHARMA

CIS BIOPHARMA at annual Swiss Biotech CEO meeting

Bern, Switzerland, Friday, January 31, 2025 – CIS BIOPHARMA, a leading oncology-focused biotech company, was invited to attend the annual Swiss Biotech Association meeting.

The event offered insight into recent members› success stories – such as the transaction of Yellow Jersey Therapies with J&J, presented by the sucessful entrepreneur David Urech. 

Christoph Schäfer, CEO, says: «During the one-day meeting I had the opportunity to connect with peers and exchange personal insights into key success factors and the fundamentals in our industry.»

«The meeting is inspiring as it demonstrates the innovation power of the Swiss biotech community, consisting of more than 1’500 biotech companies. We are proud to be contributing to the success of our industry.» 

About CIS BIOPHARMA AG

CIS BIOPHARMA is a privately-owned, Basel-based oncology company developing next-generation immuno-conjugates to address aggressive forms of tumors. The company’s product pipeline includes antibody-drug conjugates, ADCs, and radioligand therapies, RLTs,  that selectively target tumor cells. CIS BIOPHARMA is committed to helping cancer patients live longer and better lives.

 

We pioneer more effective cancer therapies to help cancer patients live longer and better lives.

Contact

CIS BIOPHARMA AG

Hauptstrasse 159
4416 Bubendorf
Switzerland

+41 61 935 53 33
hello@cisbiopharma.com

Copyright © 2024 CIS BIOPHARMA AG
Design by admaxx.ch